A Xarelto bleeding death lawsuit has been filed on behalf the estate of an Ohio woman, who allegedly bled to death after using the blood thinner.

Plaintiff-decedent Charme Mae D. ingested Xarelto from approximately July 22, 2014 to December 15, 2014 and suffered with a lower gastrointestinal hemorrhage and severe anemia.

These injuries ultimately led to Charme Mae’s alleged Xarelto bleeding death.

Charme Mae is represented by plaintiffs Amy P., the Special Administrator of her estate, and her surviving son, Terry J.

Xarelto Bleeding Death Lawsuit Allegations

The Xarelto bleeding death lawsuit claims that Bayer heavily marketed Xarelto by exaggerating the benefits and downplaying the risks and side effects of the drug in its advertisements, failing to warn of the lack of a reversal agent should a patient suffer internal bleeding.

Amy and Terry are pursuing a wrongful death claim against the manufacturers of Xarelto, further asserting that the drug makers aggressively promoted Xarelto’s advantages compared to predecessor Coumadin (warfarin).

One selling point is that Xarelto does not require regular blood monitoring or have dietary restrictions as Coumadin does.

In December 2014, the Judicial Panel on Multidistrict Litigation (JPML) consolidated all federally-filed Xarelto lawsuits against Janssen Pharmaceuticals and Bayer in a multidistrict litigation in the Eastern District of Louisiana under U.S. District Judge Eldon Fallon.

In the Xarelto bleeding lawsuits that have been filed, some of the allegations include that the manufacturers ignored patient safety and failed to warn about the significant risks with the new generation anticoagulant.

In particular, in the event of a serious bleeding incident there is no available reversal agent that can be used to stop the bleeding.

What is Xarelto?

Xarelto is a blood thinner initially approved by the U.S. Food and Drug Administration (FDA) in July 2011 to prevent strokes in patients who recently underwent hip and knee replacements.

It was also later approved for use in patients with non-valvular atrial fibrillation, or an irregular heartbeat, and to treat or reduce the recurrence of deep vein thrombosis and pulmonary embolism.

Since Xarelto was first approved, there have been several reports of bleeding events for those taking Xarelto, including gastrointestinal bleeding, hemmorhagic strokes, brain hemorrhages, and death.

Xarelto bleeding lawsuits in the Louisiana MDL allege that use of the drug caused serious internal bleeding.

The Xarelto bleeding lawsuits name as defendants Bayer Healthcare, Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals.

Many of these lawsuits are filed on behalf of loved ones who suffered Xarelto bleeding death.

More specificially, these Xarelto bleeding death lawsuits accuse Bayer and Janssen of failing to warn consumers that Xarelto does not have an antidote, leaving doctors without any effective means to treat and stabilize patients who experienced uncontrolled and excessive bleeding.

The Xarelto Bleeding Death Lawsuit MDL is In Re: Xarelto Products Liability Litigation, MDL No. 2592, in the U.S. District Court for the Eastern District of Louisiana.